CSIMarket
 


Oncocyte Corporation  (OCX)
Other Ticker:  
 


Oncocyte's Gross Profit Margin by quarter

Trends, Rankings, Statistics



OCX Gross Profit Margin (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Revenue Change 946.34 % -57.56 % -43.65 % 107.22 % -
Seq. Revenue Change -7.34 % 68.36 % -94.23 % 11519.51 % -96.24 %
Revenue In Millions $0.43 $0.46 $0.28 $4.76 $0.04
Gross Profit Margin 57.81 % 58.75 % 3.64 % 42.04 % -2863.41 %
Gross Profit Margin Total Ranking # 2184 # 2254 # 4361 # 3207 #
Gross Profit In Millions $0.25 $0.27 $0.01 $2.00 $-1.17
Y / Y Gross Profit Change - - - 88.61 % -
Seq. Gross Profit Change -8.82 % 2620 % -99.5 % - -


Commenting Third Quarter 2023 Gross Profit Margin
Oncocyte Corporation experienced contraction in Gross Profit by -8.82 % to $0 millions and Revenue by -7.34 %, while Gross Profit Margin fell to 57.81 %, above company's average Gross Profit Margin.

Observing third quarter 2023 results within In Vitro & In Vivo Diagnostic Substances industry 8 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2184, from total ranking in previous quarter at 2254.
Learn about Gross Margin
OCX's Gross Profit Margin third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 9
Healthcare Sector # 484
Overall # 2178

Gross Profit Margin Statistics
High Average Low
58.75 % 40.46 % 3.64 %
(Jun 30 2023)   (Mar 31 2023)




Other Gross Profit Margin Profitability Ratios
OCX's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
OCX's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for OCX's Competitors
Gross Profit Margin Profit Margin for Oncocyte's Suppliers
Gross Profit Margin Profit Margin for OCX's Customers

You may also want to know
OCX's Annual Growth Rates OCX's Profitability Ratios OCX's Asset Turnover Ratio OCX's Dividend Growth
OCX's Roe OCX's Valuation Ratios OCX's Financial Strength Ratios OCX's Gross Profit Growth
OCX's Roa OCX's Inventory Turnover Ratio OCX's Growth Rates OCX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginSep 30 2023 MRQ Gross ProfitSep 30 2023 MRQ Revenue
Cardio Diagnostics Holdings Inc   100.00 %$ 0.010 $ 0.010 
Celldex Therapeutics inc   100.00 %$ 1.517 $ 1.517 
Intellia Therapeutics Inc   100.00 %$ 11.992 $ 11.992 
Volitionrx Limited  100.00 %$ 0.165 $ 0.165 
Myriad Genetics Inc   69.98 %$ 134.300 $ 191.900 
Lantheus Holdings Inc   62.69 %$ 199.951 $ 318.951 
Idexx Laboratories Inc  59.89 %$ 547.982 $ 914.982 
Aspira Women s Health Inc   58.95 %$ 1.307 $ 2.217 
Oncocyte Corporation  57.81 %$ 0.248 $ 0.429 
Neogen Corporation  51.04 %$ 116.761 $ 228.761 
Quidelortho Corp  49.48 %$ 368.100 $ 744.000 
Immucell Corp  24.05 %$ 1.267 $ 5.267 
Biomerica Inc   24.05 %$ 0.412 $ 1.713 
Alpha Teknova Inc   19.70 %$ 1.472 $ 7.472 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com